AU2017268633A1 — Compositions and methods for lowering triglycerides without raising ldl-c levels

USPTO Abstract

Abstract Provided herein are methods of preventing and/or treating myocardial infarction and/or stroke in a subject by administering ethyl eicosapentaenoate (E-EPA). Preferably, the subject is previously identified as having dyslipidemia, is on stable statin therapy and has a fasting baseline triglyceride level of about 200 mg/dL to about 500 mg/dL and optionally has established cardiovascular disease or has a high risk of developing cardiovascular disease. Compositions may be formulated for daily administration to provide about 4 g of the ethyl eicosapentaenoate per day. Further provided are methods of lowering triglyceride levels in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl, by administering polyunsaturated fatty acids, for example about Ig to about 4g of eicosapentaenoic acid (EPA) per day. Such therapy, when used daily for 12 weeks, lowers fasting triglycerides and decreases LDL-C, or does not increase LDL-C.